This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Takei, M.
Right arrow Articles by Hosaka, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Takei, M.
Right arrow Articles by Hosaka, M.

 Previous Article

Antimicrobial Agents and Chemotherapy, October 2002, p. 3337-3338, Vol. 46, No. 10
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.10.3337-3338.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

LETTER TO THE EDITOR

Contribution of the C-8-Methoxy Group of Gatifloxacin to Inhibition of Type II Topoisomerases of Staphylococcus aureus


arrow
LETTER
 
Gatifloxacin is a recently marketed quinolone with an enhanced activity against gram-positive bacteria compared with that of ciprofloxacin (4, 12, 13, 18). The structural differences between gatifloxacin and ciprofloxacin are substituents at the C-8 position of the quinolone nucleus (gatifloxacin, C-8-methoxy; ciprofloxacin, C-8-H) and at the C-3' position of the piperazinyl moiety of the C-7 position (gatifloxacin, C-3'-methyl; ciprofloxacin, C-3'-H). Several studies have directed attention to substituents at the C-8 position of the quinolone nucleus (1, 2, 5-10, 14, 15, 19, 20). Introduction of the methoxy group at the C-8 position was thought to ensure potent activity against gram-positive bacteria (2, 6, 9, 20). However, there have been few studies on the effect of C-8 substituents against type II topoisomerases. Thus, to investigate the effect of the C-8 and C-3' substituents of gatifloxacin against type II topoisomerases in Staphylococcus aureus, the activities of the quinolones AM-1121 (C-8-H, C-3'-methyl) and AM-1147 (C-8-methoxy, C-3'-H), which are structurally related to gatifloxacin,Go were compared with those of gatifloxacin and ciprofloxacin.


View this table:
[in this window]
[in a new window]
  		TABLE 1. Target inhibition and antibacterial activity of gatifloxacin and its related compounds

The quinolones tested were synthesized in-house. The bacterial strain used in this study was the quinolone-susceptible clinical isolate S. aureus MS5935 (3). MICs were determined by using agar dilution methodology according to NCCLS guidelines (11).

The GyrA and GyrB subunits of DNA gyrase and the GrlA and GrlB subunits of topoisomerase IV of MS5935 were prepared by a method described previously (16, 17). The activities of each enzyme were determined by a method described previously (16, 17). The effects of the quinolones were evaluated based on the concentrations required to inhibit 50% of the enzyme reaction (IC50s).

The IC50s of C-8-methoxy compounds (gatifloxacin and AM-1147) against topoisomerase IV were almost equal to those of their C-8-H counterparts (AM-1121 and ciprofloxacin), whereas the inhibitory activities of C-8-methoxy compounds against DNA gyrase were about six times higher than those of their C-8-H counterparts (Table 1; Fig. 1). The C-3'-methyl moiety had little effect on the inhibitory activity against both DNA gyrase and topoisomerase IV. These results indicate that introduction of the C-8-methoxy group to the quinolone ring enhances the inhibitory activity against DNA gyrase without exerting influence on topoisomerase IV inhibition.



View larger version (26K):
[in this window]
[in a new window]
  		FIG. 1. Inhibitory activities of gatifloxacin and its related compounds against topoisomerase IV (A) and DNA gyrase (B).

The C-8-methoxy compounds showed two- to fourfold-lower MICs than their C-8-H counterparts. On the other hand, the antibacterial activities of C-3'-methyl compounds were similar or slightly superior to those of their C-3'-H counterparts. These results indicate that the C-8-methoxy group of these compounds has a greater effect on the increment of the activity against the wild-type strain, whereas the C-3'-methyl group is slightly involved in the increment of this activity.

It was previously reported that the inhibition of both target enzymes contributes to the antibacterial activities of quinolones because the antibacterial activities of most quinolones were decreased by both the grlA and gyrA mutations (17). Therefore, it is suggested that an increase in the inhibitory activity of the C-8-methoxy compounds against DNA gyrase is the possible mechanism underlying their potent antibacterial activity.

In summary, introduction of the methoxy group at the C-8position of the quinolone nucleus enhances inhibitory activity against DNA gyrase, leading to the potent activity of gatifloxacin against S. aureus.


arrow
REFERENCES
 
    1
  1. Dong, Y., C. Xu, X. Zhao, J. Domagala, and K. Drlica. 1998. Fluoroquinolone action against mycobacteria: effects of C-8 substituents on growth, survival, and resistance. Antimicrob. Agents Chemother. 42:2978-2984.[Abstract/Free Full Text]
    2. 2
  2. Fukuda, H., R. Kishii, M. Takei, and M. Hosaka. 2001. Contribution of the 8-methoxy group of gatifloxacin to resistance-selectivity, target-preference, and antibacterial activity in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45:1649-1653.[Abstract/Free Full Text]
    3. 3
  3. Hori, S., Y. Ohshita, Y. Utsui, and K. Hiramatsu. 1993. Sequential acquisition of norfloxacin and ofloxacin resistance by methicillin-resistant and -susceptible Staphylococcus aureus. Antimicrob. Agents Chemother. 37:2278-2284.[Abstract/Free Full Text]
    4. 4
  4. Hosaka, M., T. Yasue, H. Fukuda, H. Tomizawa, H. Aoyama, and K. Hirai. 1992. In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone. Antimicrob. Agents Chemother. 36:2108-2117.[Abstract/Free Full Text]
    5. 5
  5. Ince, D., and D. C. Hooper. 2001. Mechanisms and frequency of resistance to gatifloxacin in comparison to AM-1121 and ciprofloxacin in Staphylococcus aureus. Antimicrob. Agents Chemother. 45:2755-2764.[Abstract/Free Full Text]
    6. 6
  6. Ito, T., M. Matsumoto, and T. Nishino. 1995. Improved bactericidal activity of Q-35 against quinolone-resistant staphylococci. Antimicrob. Agents Chemother. 39:1522-1525.[Abstract]
    7. 7
  7. Kitamura, A., K. Hoshino, Y. Kimura, I. Hayakawa, and K. Sato. 1995. Contribution of the C-8 substituent of DU-6859a, a new potent fluoroquinolone, to its activity against DNA gyrase mutants of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 39:1467-1471.[Abstract]
    8. 8
  8. Lu, T., X. Zhao, and K. Drlica. 1999. Gatifloxacin activity against quinolone-resistant gyrase: allele-specific enhancement of bacteriostatic and bactericidal activities by the C-8-methoxy group. Antimicrob. Agents Chemother. 43:2969-2974.[Abstract/Free Full Text]
    9. 9
  9. Lu, T., X. Zhao, A. Drlica-Wagner, J.-Y. Wang, J. Domagala, and K. Drlica. 2001. Enhancement of fluoroquinolone activity by C-8 halogen and methoxy moieties: action against a gyrase resistance mutant of Mycobacterium smegmatis and a gyrase-topoisomerase IV double mutant of Staphylococcus aureus. Antimicrob. Agents Chemother. 45:2703-2709.[Abstract/Free Full Text]
    10. 10
  10. Marutani, K., M. Matsumoto, Y. Otabe, M. Nagamuta, K. Tanaka, A. Miyoshi, T. Hasegawa, H. Nagano, S. Matsubara, R. Kamide, T. Yokota, F. Matsumoto, and Y. Ueda. 1993. Reduced phototoxicity of a fluoroquinolone antibacterial agent with a methoxy group at the 8 position in mice irradiated with long-wavelength UV light. Antimicrob. Agents Chemother. 37:2217-2223.[Abstract/Free Full Text]
    11. 11
  11. National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. Approved standard M7-A4. National Committee for Clinical Laboratory Standards, Wayne, Pa.
    12. 12
  12. Odland, B. A., R. N. Jones, A. Verhoef, A. Fluit, M. L. Beach, and the SENTRY Antimicrobial Surveillance Group (Americas and Europe). 1999. Antimicrobial activity of gatifloxacin (AM-1155, CG5501), and four other fluoroquinolones tested against 2,284 recent clinical strains of Streptococcus pneumoniae from Europe, Latin America, Canada, and the United States. Diagn. Microbiol. Infect. Dis. 34:315-320.[CrossRef][Medline]
    13. 13
  13. Reinert, R. R., A. Al Lahham, S. Lemmen, and R. Lütticken. 2000. In vitro activity of gatifloxacin against Streptococcus pneumoniae isolates in Germany. J. Antimicrob. Chemother. 46:854-856.[Free Full Text]
    14. 14
  14. Renau, T. E., J. W. Gage, J. A. Dever, G. E. Roland, E. T. Joannides, M. A. Shapiro, J. P. Sanchez, S. J. Gracheck, J. M. Domagala, M. R. Jacobs, and R. C. Reynolds. 1996. Structure-activity relationships of quinolone agents against mycobacteria: effect of structural modifications at the 8 position. Antimicrob. Agents Chemother. 40:2363-2368.[Abstract]
    15. 15
  15. Sindelar, G., X. Zhao, A. Liew, Y. Dong, T. Lu, J. Zhou, J. Domagala, and K. Drlica. 2000. Mutant prevention concentration as a measure of fluoroquinolone potency against mycobacteria. Antimicrob. Agents Chemother. 44:3337-3343.[Abstract/Free Full Text]
    16. 16
  16. Takei, M., H. Fukuda, T. Yasue, M. Hosaka, and Y. Oomori. 1998. Inhibitory activities of gatifloxacin (AM-1155), a newly developed fluoroquinolone, against bacterial and mammalian type II topoisomerases. Antimicrob. Agents Chemother. 42:2678-2681.[Abstract/Free Full Text]
    17. 17
  17. Takei, M., H. Fukuda, R. Kishii, and M. Hosaka. 2001. Target preference of 15 quinolones in Staphylococcus aureus, based on antibacterial activities and target inhibition. Antimicrob. Agents Chemother. 45:3544-3547.[Abstract/Free Full Text]
    18. 18
  18. Tsurumaki, Y., H. Manda, M. Takei, and M. Hosaka. 2000. In vitro antimicrobial activity of gatifloxacin against 873 clinical isolates from respiratory tract, urinary tract and surgical infections during 1997-1998 in Japan. J. Antimicrob. Chemother. 45:685-689.[Abstract/Free Full Text]
    19. 19
  19. Zhao, X., C. Xu, J. Domagala, and K. Drlica. 1997. DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance. Proc. Natl. Acad. Sci. USA 94:13991-13996.[Abstract/Free Full Text]
    20. 20
  20. Zhao, X., J.-Y. Wang, C. Xu, Y. Dong, J. Zhou, J. Domagala, and K. Drlica. 1998. Killing of Staphylococcus aureus by C-8-methoxy fluoroquinolones. Antimicrob. Agents Chemother. 42:956-958.[Abstract/Free Full Text]
Masaya Takei*
Hideyuki Fukuda
Ryuta Kishii
Youko Kadowaki
Yukiko Atobe
Masaki Hosaka
Discovery Research Laboratories, Kyorin Pharmaceutical Co., Ltd., 2399-1 Nogi, Shimotsuga, Tochigi 329-0114, Japan

* Phone: 81-280-56-2201 Fax: 81-280-57-1293 E-mail: masaya.takei{at}mb2.kyorin-pharm.co.jp

Antimicrobial Agents and Chemotherapy, October 2002, p. 3337-3338, Vol. 46, No. 10
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.10.3337-3338.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Takei, M.
Right arrow Articles by Hosaka, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Takei, M.
Right arrow Articles by Hosaka, M.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»